การประชุมคณะทำงานติดตามผลประสิทธิภาพของยารักษาโรคเขตร้อนที่ถูกละเลย ครั้งที่ 10 เมืองเกนต์ ประเทศเบลเยียม

Helminth control programmes based on preventive chemotherapy against soiltransmitted helminthiases and schistosomiasis are continuing to scale up. In 2021, the global coverage of preventive chemotherapy reached 62.2% for soil-transmitted helminthiases and 40.3% for schistosomiasis; more than 650 million individuals were treated with albendazole and mebendazole for soil-transmitted helminthiases and with praziquantel for schistosomiasis.

The expansion of preventive chemotherapy can potentially risk triggering anthelminthic drug resistance and put at stake the long-term public health benefits of the intervention. Antimicrobial resistance is not yet a public health problem in human helminthiases, as opposed to helminths of veterinary importance.